Aerosolization of low phase transition temperature liposomal tobramycin as a dry powder in an animal model of chronic pulmonary infection caused by Pseudomonas aeruginosa.
Eradication of mucoid Pseudomonas aeruginosa in an animal model of chronic pulmonary infection has been previously demonstrated following the intratracheal administration of Fluidosomes, a low phase transition temperature (low T(C)) liposomal tobramycin preparation administered in liquid form (Beaulac et al., Antimicrob. Agents Chemother., 40, 665-669, 1996). In the present work, the same liposomal formulation was administered as a dry powder aerosol to an animal model of chronic pulmonary infection in view of a possible clinical development in cystic fibrosis patients. Chronic infection was established by intratracheal administration of 10(5) cfu of a mucoid variant of P. aeruginosa, PA 508, prepared in agar beads. Sixteen hours after one aerosol treatment, the cfu counts performed on lungs (pair) treated with liposomal tobramycin were of 4.31x10(5) cfu/lungs comparatively to 1.32x10(8) and 3.02x10(8) cfu/lungs respectively in untreated and in lungs treated with free antibiotic. Considering the quantity of liposome-tobramycin that has reached the lungs, the results suggest that aerosolization of low T(C) liposomal tobramycin used as a dry powder preparation could be an effective way of treating chronic pulmonary infection caused by Pseudomonas.
Beaulac
C
C
Department of Microbiology and Immunology, Faculty of Medicine, Université de Montréal, Québec, Canada.
Sachetelli
S
S
Lagacé
J
J
D000336:Aerosols; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D002908:Chronic Disease; D004195:Disease Models, Animal; D004337:Drug Carriers; D008081:Liposomes; D008171:Lung Diseases / Q000188:drug therapy*; D011208:Powders; D011552:Pseudomonas Infections / Q000188:drug therapy*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013696:Temperature; D014031:Tobramycin / Q000008:administration & dosage*
D000336:Aerosols; D000900:Anti-Bacterial Agents; D004337:Drug Carriers; D008081:Liposomes; D011208:Powders; D014031:Tobramycin